Imbed Biosciences

Imbed Biosciences is a medical device company that develops nanotechnology-based wound care products using its proprietary SAMatrix platform. The platform integrates multiple wound care agents—including broad-spectrum antimicrobial silver and lidocaine for pain management—into an ultra-thin, fully synthetic matrix composed of bioresorbable fibers. The product portfolio includes Microlyte for chronic wounds, Pelashield for burn and acute wounds, Surgaflex for surgical wounds, and the PainGuard line that adds lidocaine for localized non-opioid pain relief. The company is registered with the U.S. FDA as a medical device manufacturer and maintains an ISO 13485:2016 certified Quality Management System. Founded in 2010 and headquartered in Madison, Wisconsin, Imbed Biosciences has raised approximately $34.3 million at the Series C stage from investors including NIH, National Science Foundation, WISC Partners, Formidable Asset Management, Niterra, WARF, and BioLab Holdings.